Genomic/Proteomic PTB Network: UAB Clinical Core Center

基因组/蛋白质组 PTB 网络：UAB 临床核心中心

• 批准号: 6943811
• 负责人: WILLIAM Walton ANDREWS
• 金额: $ 33.1万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6943811
• 关键词: biomarker; biotechnology; clinical research; clinical trials; cooperative study; cytokine; drug screening /evaluation; functional /structural genomics; gene expression; genetic markers; human genetic material tag; human pregnant subject; human subject; human therapy evaluation; patient oriented research; pregnancy disorder chemotherapy; premature infant human; premature labor; progesterone; proteomics; women' s health

DESCRIPTION (provided by applicant): Preterm birth remains the leading cause of perinatal morbidity and mortality, the rate of preterm birth continues to increase, and effective interventions to prevent preterm birth remain illusive. Investigators in the Center for Research in Women's Health at our institution have provided strong clinical research leadership in this area for 25 years. We have successfully acquired millions of dollars in federal funding to conduct clinical studies designed to improve our understanding of the pathophysiology of preterm birth as well as to test many potential interventions in prospective randomized trials. The productivity of our group has resulted in hundreds of publications in the area of preterm birth and its prevention. Our excellence in performing high quality well-designed clinical trials is widely known. Germane to this application is our particular strength and success in performing multi-center trials and providing a leadership role in research networks including the NICHD Maternal-Fetal Medicine Units Network in which we have been a participating institution for nearly 15 years. Indeed, UAB was ranked first in overall performance among the 14 centers in this Network in the most recent objective ranking of member institutions. Thus, we believe that we are particularly well-positioned, not only to effectively participate, but also to provide leadership as a Clinical Core Center in the proposed Genomic and Proteomic Network. In this application, we will describe in detail our extremely successful clinical research facilities and infrastructure. We will also emphasize our well-documented strengths including patient accrual and retention, high-quality data acquisition and entry, rapid ramp-up to initiate new trials, protocol adherence, analysis and publication productivity, and collaborative success in protocol development and implementation in the NICHD MFMU Network which appears to be a model upon which the proposed new network is based. We believe that our enthusiasm and commitment to this project will be evident and we believe that our qualifications will be very competitive for consideration.

描述（由申请人提供）：早产仍然是围产期发病率和死亡率的主要原因，早产率继续增加，并有效防止早产的干预措施仍然是虚幻的。我们机构妇女健康研究中心的研究人员在该领域提供了强大的临床研究领导，已有25年了。我们已经成功地获得了数百万美元的联邦资金，以进行临床研究，旨在提高我们对早产的病理生理学的理解，并在前瞻性随机试验中测试许多潜在的干预措施。我们小组的生产力导致了早产及其预防领域的数百个出版物。我们在执行高质量精心设计的临床试验方面的卓越表现是广为人知的。该应用程序的理由是我们在进行多中心试验并在研究网络中提供领导角色的特殊优势和成功，包括NICHD母体 - 私人医学部门网络，我们已经成为参与机构已有近15年了。确实，在成员机构的最新目标排名中，UAB在该网络中的14个中心中排名第一。因此，我们认为我们的位置特别良好，不仅可以有效地参与，而且还可以在拟议的基因组和蛋白质组学网络中作为临床核心中心提供领导力。在此应用程序中，我们将详细描述我们非常成功的临床研究设施和基础设施。我们还将强调我们有据可查的优势，包括患者应计和保留率，高质量的数据获取和进入，快速升级以启动新的试验，协议依从性，分析和出版物生产力以及在NICHD MFMU网络中的协议开发和实施方面的协作成功，这似乎是拟议的新网络基于新网络的模型。我们认为，我们对该项目的热情和承诺将是显而易见的，我们相信我们的资格将非常有竞争力。